MedTrace Logo

Effect of PreforPro® on Urinary and Vaginal Health

NCT05590195 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-01-09

No results posted yet for this study

Summary

This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater \> 6.7 X 107 PFU/gram) on bacterial vaginosis.

Conditions

  • Bacterial Vaginosis
  • Bacterial Infections
  • Bacterial Vaginosis | Vaginal | Microbiology
  • Vaginal Infection

Interventions

DRUG

Preforpro

Preforpro will be investigated to improve vaginal health in women with BV.

OTHER

Placebo

Placebo capsules manufactured to look like Preforpro capsules

Sponsors & Collaborators

  • Deerland Enzymes

    collaborator INDUSTRY

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    collaborator OTHER

  • St. Joseph's Health Care London

    collaborator OTHER

  • Jeremy Burton

    lead OTHER

Principal Investigators

  • Jermy Burton · Lawson HRI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-03-01
Completion
2025-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590195 on ClinicalTrials.gov